Search Results - "Beuzeboc, P"

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients by Laé, M., Couturier, J., Oudard, S., Radvanyi, F., Beuzeboc, P., Vieillefond, A.

“…This study assessed the human epidermal growth factor receptor-2 (HER2) protein expression and its relationship with gene amplification in invasive bladder…”
Get full text

Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial by Fléchon, A., Pouessel, D., Ferlay, C., Perol, D., Beuzeboc, P., Gravis, G., Joly, F., Oudard, S., Deplanque, G., Zanetta, S., Fargeot, P., Priou, F., Droz, J.P., Culine, S.

“…In the evolution of metastatic castration-resistant prostate cancer (mCRPC), patients present visceral metastases with or without neuroendocrine…”
Get full text

Concurrent Use of Radiosurgery for Brain Metastases and TDM1 in HER2-Positive Metastatic Breast by Geraud, A, Beuzeboc, P, Xu, H, Kirova, Y.M

Get full text

Patient reported outcomes: Web-monitoring versus nurse assessment to improve anticancer therapies by Korostelev, M., Sejean, K., Lepage, C., Stevens, J., Bonan, B., Beuzeboc, P., Scotté, F.

Get full text

Re: Multicenter Phase II Study of Combined Neoadjuvant Docetaxel and Hormone Therapy before Radical Prostatectomy for Patients with High Risk Localized Prostate Cancer by Beuzeboc, P

Get full text

Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience by Staudacher, L., Cottu, P.H., Diéras, V., Vincent-Salomon, A., Guilhaume, M.N., Escalup, L., Dorval, T., Beuzeboc, P., Mignot, L., Pierga, J.Y.

“…Although recent experimental data strongly suggest that platinum-based chemotherapy (PBCT) could improve the outcome of triple-negative breast cancer (TNBC),…”
Get full text

Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study by Jacob, J., Belin, L., Pierga, J.-Y., Gobillion, A., Vincent-Salomon, A., Dendale, R., Beuzeboc, P., Campana, F., Fourquet, A., Kirova, Y. M.

“…This single-center prospective study aims to assess the outcomes and the toxicities related to the concurrent administration of trastuzumab (T) with adjuvant…”
Get full text

CCAFU french national guidelines 2016-2018 on prostate cancer by Rozet, F, Hennequin, C, Beauval, J-B, Beuzeboc, P, Cormier, L, Fromont, G, Mongiat-Artus, P, Ouzzane, A, Ploussard, G, Azria, D, Brenot-Rossi, I, Cancel-Tassin, G, Cussenot, O, Lebret, T, Rebillard, X, Soulié, M, Renard-Penna, R, Méjean, A

“…The purpose of the guidelines national committee CCAFU was to propose updated french guidelines for localized and metastatic prostate cancer (PCa). A Medline…”
Get more information

Breast cancer (BC) treatment (tx) with everolimus (EVE) and exemestane (EXE) in hormone receptor positive (HR+)/ HER2-negative (HER2−) postmenopausal women: Final analysis of the French observational TANGO study by Villanueva, C., Yazbek, G., Beuzeboc, P., Viel, E., Dohollou, N., Luporsi, E., Eymard, J.-C., Levy, E., Mouret-Reynier, M.-A., Dourthe, L.-M., Malaurie, E., Madelenat, M., Denden, A., Antoine, E.-C.

Get full text

Targeting HER2 in other tumor types by SCHOLL, S, BEUZEBOC, P, POUILLART, P

“…The human epidermal growth factor receptor-2 (HER2) is overexpressed/amplified in a range of tumor types including breast, ovarian, bladder, salivary gland,…”
Get full text

2191 Decreased overall survival in colorectal cancer patients with renal insufficiency by Janus, N, Ray-Coquard, I, Beuzeboc, P, Thariat, J, Deray, G, Launay-Vacher, V

Get full text

CCAFU Recommendations 2013: Prostate cancer by Salomon, L, Bastide, C, Beuzeboc, P, Cormier, L, Fromont, G, Hennequin, C, Mongiat-Artus, P, Peyromaure, M, Ploussard, G, Renard-Penna, R, Rozet, F, Azria, D, Coloby, P, Molinié, V, Ravery, V, Rebillard, X, Richaud, P, Villers, A, Soulié, M

“…The sub Comittee prostate of the CCAFU established guidelines for diagnostic, treatment, evaluation and standart of care of prostate cancer. Guidelines 2010…”
Get more information

Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients by Oudard, S., Banu, E., Scotte, F., Banu, A., Medioni, J., Beuzeboc, P., Joly, F., Ferrero, J.-M., Goldwasser, F., Andrieu, J.-M.

“…Background: We evaluated the possible use of prostate-specific antigen doubling time (PSA-DT) before chemotherapy initiation as a surrogate marker of survival…”
Get full text

French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020 by Rozet, F, Hennequin, C, Beuzeboc, P, Mathieu, R, Mongiat-Artus, P, Beauval, J-B, Cormier, L, Fromont-Hankard, G, Ploussard, G, Renard-Penna, R, Brureau, L, Méjean, A

“…The aim of the Cancerology Committee of the French Association of urology (CCAFU) is to propose an update of the guidelines in the management of…”
Get more information

The androgen receptor for the radiation oncologist by Quero, L., Rozet, F., Beuzeboc, P., Hennequin, C.

“…Androgen deprivation therapy is widely used in combination with radiotherapy for the treatment of prostate cancer. The knowledge of the biology of the androgen…”
Get full text

Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA by Spano, J.-P, Beuzeboc, P, Coeffic, D, Arnould, L, Lortholary, A, Andre, F, Ferrero, J.-M

“…Abstract Purpose The LORHA study described the clinical features of patients and tumours in long-term responders from a subset of breast cancer patients who…”
Get full text

Preliminary results of the concurrent use of radiotherapy for bone metastases and trastuzumab emtansine in patients with HER2-positive metastatic breast cancer by Géraud, A., Xu, H.P., Beuzeboc, P., Kirova, Y.M.

Get full text

Efficacy and tolerance of everolimus in 123 consecutive advanced ER positive, HER2 negative breast cancer patients. A two center retrospective study by Chocteau-Bouju, D, Chakiba, C, Mignot, L, Madranges, N, Pierga, J.-Y, Beuzeboc, P, Quenel-Tueux, N, Dieras, V, Bonnefoi, H, Debled, M, Cottu, P

“…Abstract Background Since the publication of the Bolero-2 trial, everolimus has entered the routine care for advanced endocrine resistant luminal breast cancer…”
Get full text

Cardiotoxicity of the Association Trastuzumab–Locoregional Breast Radiation Therapy: A Prospective Monocentric Study by Jacob, J, Belin, L, Pierga, J, Gobillion, A, Dendale, R, Beuzeboc, P, Campana, F, Fourquet, A, Kirova, Y.M

Get full text

Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age by Pierga, J.-Y., Girre, V., Laurence, V., Asselain, B., Diéras, V., Jouve, M., Beuzeboc, P., Fourquet, A., Nos, C., Sigal-Zafrani, B., Pouillart, P.

“…From 1981 to 1995, 1755 patients aged 70 years or over who had nonmetastatic unilateral breast carcinoma received curative local or regional treatment in our…”
Get full text